Source BioScience Acquires Select Pharma Laboratories Ltd
Operating in the pharmaceutical, animal health and medical devices sectors, Select is a leading provider of stability storage and testing services, with a strong commercial presence in the UK and overseas. Located in Stirling, Scotland, Select’s portfolio of laboratory services includes chemistry, physical and microbiological analyses for application in therapeutics batch release and product release to the EU market.
The combination of the Company’s existing services with Select’s capabilities will enable Source BioScience to offer a vertically integrated solution to customers, with environmentally controlled storage in combination with the required up- or downstream analytical testing services.
In line with the high standards synonymous with the Source BioScience brand, Select operates from GMP-approved facilities, and holds approval status with the Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration (FDA).
The acquisition of Select follows a series of successful acquisitions in recent years and will add further breadth and depth to the Source BioScience portfolio, enabling customers to access stability storage products and laboratory analyses from a single, highly accredited provider.
Dr Nick Ash, CEO of Source BioScience said:
“The acquisition of Select will provide the Company with the expertise and capability to provide stability testing services that are highly complementary to the Group’s existing stability storage services.
“Significant cross-selling opportunities are apparent with our existing customer base, enabling them to reduce the number of service providers and de-risk the process by avoiding unnecessary sample transfers.
“At Source BioScience we are dedicated to delivering the highest standard of service to our customers, and the Select team will bring significant experience and knowledge and enhance the capabilities of the Group.”
Find out more
For further information, please contact:
Source BioScience plc
Dr Nick Ash, CEO
Tel: +44 (0) 115 973 9010